07.30.15
Baxalta
2Q Revenues: $1.4 billion (-2%)
2Q Earnings: $272 million (-24%)
YTD Revenues: $2.8 billion (flat)
YTD Earnings: n/a
Comments: Hematology revenues were $855 million, excluding the impact of foreign exchange, grew 6% in the quarter driven by ADVATE, a treatment for hemophilia A, and double-digit growth of FEIBA, an inhibitor treatment. Newly launched products also contributed to growth, including RIXUBIS for the treatment of hemophilia B, and OBIZUR for the treatment of acquired hemophilia A. Immunology sales were $574 million, excluding the impact of foreign currency, grew 10% driven by immunoglobulin therapies and continued launch success of HYQVIA for adults with primary immunodeficiency. In the quarter, the company completed the ONCASPAR portfolio acquisition from Sigma-Tau Finanziaria for approximately $900 million.
2Q Revenues: $1.4 billion (-2%)
2Q Earnings: $272 million (-24%)
YTD Revenues: $2.8 billion (flat)
YTD Earnings: n/a
Comments: Hematology revenues were $855 million, excluding the impact of foreign exchange, grew 6% in the quarter driven by ADVATE, a treatment for hemophilia A, and double-digit growth of FEIBA, an inhibitor treatment. Newly launched products also contributed to growth, including RIXUBIS for the treatment of hemophilia B, and OBIZUR for the treatment of acquired hemophilia A. Immunology sales were $574 million, excluding the impact of foreign currency, grew 10% driven by immunoglobulin therapies and continued launch success of HYQVIA for adults with primary immunodeficiency. In the quarter, the company completed the ONCASPAR portfolio acquisition from Sigma-Tau Finanziaria for approximately $900 million.